|
KMID : 0360319920240020288
|
|
Journal of Korean Cancer Research Association
1992 Volume.24 No. 2 p.288 ~ p.292
|
|
|
Effects of Ondansetron in the Prevention of Nausea and Vomiting Associated with Chemotherapy in Acute Myelocytic Leukemia
|
|
민우성
진종률/한치화/박종원/김춘추/김동집
|
|
|
Abstract
|
|
|
Chemotherapy induced nausea and vomiting continues to be a significant problem in the care of patients receiving cancer chemotherapy. Existing antiemetic regimens such as highdose metoclopramide have demonstrated clinical effecacy.
Originally, the antiemetic effect of metoclopramide was thought to be mediated by dopamine receptor blockade and so produced adverse events like as extrapyramidal reactions.
Ondansetron(GR 38032 F)is a selective antagonist of serotonin subtype 3 receptors, and is a potent antiemetic agent when used in patients receiving cancer chemotherapy.
Ondansetron is at least as effective as metoclopramide in the management of 6-TG/Ara-c/Daunorubicin induced emesis in Acute myelocytic leukemia.
1) The antiemetic efficacy of ondansetron showed eleven(73.3%) patients had a compete response to therapy and three(20%) patients had a major response, there is one patient who had<5 emetic episodes(minor response)but no patients who had
treatment
failure in 15 AML patients.
2) The adverse events of ondansetron showed two patients had headache and one patient had a loose stool.
Elevation in serum aspartate aminotransferase(AST)and ALT ocurred in three patients, but in patients with normal baseline enzyme levels. AST values increased to less than twice the upper limit of normal valuses.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
 
|